Contribuciones a las Ciencias Sociales,
Journal Year:
2023,
Volume and Issue:
16(12), P. 33098 - 33109
Published: Dec. 22, 2023
O
autismo
é
um
distúrbio
neuropsiquiátrico,
que
se
classifica
como
transtorno
cognitivo,
no
qual
o
paciente
apresenta
alterações
comportamento,
desenvolvimento
e
comunicação,
os
sintomas
podem
variar
conforme
grau
de
comprometimento.
Os
portadores
TEA
(Transtorno
do
espetro
autista)
também
são
mais
pré-dispostos
a
possuírem
outras
comorbidades
prejudicam
ainda
qualidade
vida.
Devido
as
dificuldades
apresentadas
pelos
tratamentos
usuais
dos
pacientes,
eram
compostos
por
antipsicóticos,
inibidores
seletivos
da
recaptação
serotonina,
estimulantes
ansiolítico,
pela
notoriedade
relação
intima
entre
sistema
endocanabinóide
(ECS)
foram
feitos
muitos
estudos
sobre
inclusão
cannabis
tratamento.
Desta
forma,
será
elaborada
uma
revisão
narrativa
forma
sistematizada
artigos
utilizaram
canabidiol
tratamento
TEA.
Serão
utilizadas
bases
dados
SciELO,
Google
Escolar,
Medline
Pubmed,
sendo
utilizados
descritores
seguir
em
cada
base:
autismo,
cannabis,
tratamento,
resumo
título.
As
pesquisas
incluídas
ser
publicadas
periódicos
nacionais
internacionais,
nos
idiomas
inglês
português.
serão
selecionados
passarão
leitura
na
íntegra
relevantes
para
análise
interpretação
extraídos.
Behavioural Neurology,
Journal Year:
2023,
Volume and Issue:
2023, P. 1 - 17
Published: Oct. 12, 2023
Cannabidiol
(CBD),
derived
from
Cannabis
sativa,
has
gained
remarkable
attention
for
its
potential
therapeutic
applications.
This
thorough
analysis
explores
the
increasing
significance
of
CBD
in
treating
neurological
conditions
including
epilepsy,
multiple
sclerosis,
Parkinson's
disease,
and
Alzheimer's
which
present
major
healthcare
concerns
on
a
worldwide
scale.
Despite
lack
available
therapies,
been
shown
to
possess
variety
pharmacological
effects
preclinical
clinical
studies,
making
it
an
intriguing
competitor.
review
brings
together
most
recent
findings
endocannabinoid
neurotransmitter
systems,
as
well
anti-inflammatory
pathways,
that
underlie
CBD's
modes
action.
Synthesized
efficacy
safety
assessments
range
illnesses
are
included,
covering
human
trials,
vitro
animal
models.
The
investigation
includes
how
could
protect
neurons,
control
neuroinflammation,
fend
off
oxidative
stress,
manage
neuronal
excitability.
study
emphasizes
existing
studies
future
possibilities
research,
addressing
research
issues
such
regulatory
complications
contradicting
results,
advocates
further
ideal
dose
methodologies.
By
emphasizing
improve
patient
well-being,
this
presents
revised
viewpoint
suitability
intervention
illnesses.
Epilepsy & Behavior Reports,
Journal Year:
2024,
Volume and Issue:
25, P. 100651 - 100651
Published: Jan. 1, 2024
Epilepsy
is
a
heterogeneous
disorder
of
recurrent
seizures
which
often
comorbid
with
anxiety,
depression,
attention
deficit
hyperactivity
(ADHD),
intellectual
disability
(ID),
and
other
psychiatric
manifestations.
Treating
both
epilepsy
behavioral
symptoms
from
disorders
can
result
in
polypharmacy
interactions
medications
leading
to
worsened
efficacy
antiseizure
due
psychotropic
effects
worsening
medication
side
effects.
We
aim
suggest
pragmatic
strategies
for
the
neurologist
diagnosis
management
ADHD
patients
based
on
International
League
Against
(ILAE)
Pediatric
Commission
guidelines
additional
literature
review.
The
screening
tool
choice
validated
country
practice
written
language
family,
though
various
tools
advantages
disadvantages
each
will
be
discussed.
Once
diagnosed,
recent
safety
data
that
Methylphenidate,
Amphetamine,
Atomoxetine
are
generally
safe
epilepsy.
present
case
child
discuss
clinical
signs,
symptoms,
treatment
as
well
when
refer
psychiatry.
PubVet,
Journal Year:
2025,
Volume and Issue:
19(01), P. e1718 - e1718
Published: Jan. 7, 2025
In
the
current
scenario,
Cannabis
sativa
has
been
highlighted
due
to
increasing
use
of
its
components
in
treatment
various
pathologies,
both
human
and
veterinary
medicine.
The
present
study
aims
identify
ways
which
is
used
Veterinary
Medical
Clinics
today.
For
this,
a
methodology
for
bibliographic
review.
Finally,
data
found
was
compared
proven,
where
Clinic
verified
chronic
atopic
dermatitis,
epilepsy,
travel-induced
stress
urothelial
cancer
dogs,
addition
as
analgesics
osteoarthritis.
cats.
Cannabis and Cannabinoid Research,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 14, 2025
Introduction:
Medicinal
cannabis
(MC)
has
potential
therapeutic
effects
in
Tourette
Syndrome
(TS),
however
there
been
limited
research
adolescent
patients.
This
pilot
study
aimed
to
investigate
the
feasibility
of
conducting
a
randomized
placebo-controlled
crossover
trial
MC
adolescents
with
TS.
Method:
was
phase
I/II
double-blind,
cross-over
comparing
matched
placebo
aged
12-18
years
The
active
medication
Δ9-tetrahydrocannabinol
(THC)
10
mg/mL
and
CBD
15
peppermint-flavored
medium-chain
triglyceride
oil.
dose
titration
schedule
stratified
into
two
participant
weight
bands:
below
50
kg
(max
THC
mg/day)
or
≥50
20
mg/day).
Each
treatment
lasted
weeks,
4-week
washout
period.
Results:
Ten
were
(mean
age
14.8
years,
50%
male)
seven
completed
full
protocol.
Two
discontinued
due
adverse
events
(one
on
MC,
one
placebo)
lost
follow-up.
most
common
event
dizziness
(67%).
There
no
serious
events.
Among
actively
enrolled
participants,
protocol
adherence
excellent:
visits
100%,
blood
test
completions
online
questionnaire
completion
97.6%.
Medication
acceptable
63.6%.
Parents
reported
high
degree
design
acceptability.
On
Clinical
Global
Impression-Improvement
scale,
three
participants
rated
as
much
improved
compared
at
weeks.
Discussion:
findings
suggest
that
is
feasible
patients
TS
their
families.
A
fully
powered
needed
evaluate
efficacy
Journal of Palliative Medicine,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 3, 2025
Background:
Medical
cannabis
(MC)
is
increasingly
in
use
due
to
recent
cultural
and
political
changes.
Other
than
patients
with
Lennox-Gastaut
Dravet
syndrome,
there
inadequate
literature
provide
evidence-based
support
for
prescribing
MC
pediatric
patients.
Objectives:
Characterize
the
population
receiving
an
recommendation
ambulatory
palliative
care
setting
quantify
patient/family-reported
outcomes.
Design:
Retrospective
chart
review
of
electronic
medical
record
(EMR)
data.
Setting/Subjects:
Total
n
=
46
consecutive
advice
regarding
(n
42)
a
specialized
clinic
embedded
division
4
inpatient
midwestern
U.S.
hospital
between
2019
2022.
Measurements:
Demographics,
diagnosis,
symptoms,
adverse
reactions,
patient-reported
outcomes,
barriers
abstracted
from
EMR.
Results:
Our
sample
included
mean
age
11.7
years
(SD
5.4);
50%
had
neurological
diagnosis
25);
37%
14)
hematological/oncologic;
13%
6),
chronic
pain.
The
most
common
type
recommended
was
1:1
Cannabidiol
(CBD):
tetrahydrocannabinol
(THC)
tincture.
There
statistically
significant
decrease
floor
days
cost.
Totally,
35%
were
able
or
discontinue
other
medications.
Thematic
analysis
identified
four
(product
unavailable,
difficulty
obtaining
state
card,
cost,
organizational)
subjective
symptom
improvement.
Conclusions:
These
data
characterize
at
our
hospital.
Positive
outcomes
noted
across
several
domains.
seems
be
associated
lower
health
utilization,
reduced
polypharmacy,
increased
quality
life
used
without
events.
In
value-conscious
environment,
warrant
further
exploration.
NeuroMolecular Medicine,
Journal Year:
2024,
Volume and Issue:
26(1)
Published: May 14, 2024
Abstract
The
salient
features
of
autism
spectrum
disorder
(ASD)
encompass
persistent
difficulties
in
social
communication,
as
well
the
presence
restricted
and
repetitive
facets
behavior,
hobbies,
or
pursuits,
which
are
often
accompanied
with
cognitive
limitations.
Over
past
few
decades,
a
sizable
number
studies
have
been
conducted
to
enhance
our
understanding
pathophysiology
ASD.
Preclinical
rat
models
proven
be
extremely
valuable
simulating
analyzing
roles
wide
range
established
environmental
genetic
factors.
Recent
research
has
also
demonstrated
significant
involvement
endocannabinoid
system
(ECS)
pathogenesis
several
neuropsychiatric
diseases,
including
In
fact,
ECS
potential
regulate
multitude
metabolic
cellular
pathways
associated
autism,
immune
system.
Moreover,
emerged
promising
target
for
intervention
high
predictive
validity.
Particularly
noteworthy
resent
preclinical
rodents,
describe
onset
ASD-like
symptoms
after
various
pharmacological
interventions
targeting
ECS,
providing
encouraging
evidence
further
exploration
this
area.
Cannabis and Cannabinoid Research,
Journal Year:
2024,
Volume and Issue:
unknown
Published: July 24, 2024
The
literature
supports
the
benefits
of
medical
cannabis
for
core
and
comorbid
symptoms
in
autistic
individuals
anxiety-related
without
autism.
However,
no
study
has
specifically
investigated
how
cannabidiol
(CBD)-rich
affects
anxiety
subtypes
children
or
its
relationship
with
restricted
repetitive
behaviors
interests
(RRBI).
Understanding
effects
CBD-rich
treatment
on
RRBI
could
offer
more
precise
approaches
to
managing
reducing
frequency
children.
Journal of Clinical Medicine,
Journal Year:
2024,
Volume and Issue:
13(12), P. 3567 - 3567
Published: June 18, 2024
Epilepsy
is
a
disorder
characterized
by
abnormal
brain
neuron
activity,
predisposing
individuals
to
seizures.
The
International
League
Against
(ILAE)
categorizes
epilepsy
into
the
following
groups:
focal,
generalized,
generalized
and
unknown.
Infants
are
most
vulnerable
pediatric
group
condition,
with
cause
of
development
being
attributed
congenital
developmental
defects,
white
matter
damage,
intraventricular
hemorrhage,
perinatal
hypoxic-ischemic
injury,
stroke,
or
genetic
factors
such
as
mutations
in
Sodium
Channel
Protein
Type
1
Subunit
Alpha
(SCN1A)
gene.
Due
risks
associated
this
we
have
investigated
how
latest
pharmacological
treatments
for
children
impact
reduction
complete
elimination
We
reviewed
literature
from
2018
2024,
focusing
on
age
month
18
years
old,
some
studies
including
well
older
individuals.
significance
review
present
compile
research
findings
antiseizure
drugs
(ASDs),
their
effectiveness,
dosing,
adverse
effects
population,
which
can
contribute
selecting
best
drug
particular
patient.
medications
described
shown
significant
efficacy
safety
studied
patient
group,
outweighing
observed
effects.
main
aim
provide
comprehensive
summary
current
state
knowledge
regarding
newest
pharmacotherapy
childhood
epilepsy.
Developmental Neurobiology,
Journal Year:
2024,
Volume and Issue:
85(1)
Published: Nov. 27, 2024
ABSTRACT
Autism
spectrum
disorder
(ASD)
is
characterized
by
deficits
in
communication,
social
interaction,
and
repetitive
stereotyped
behaviors,
with
no
specific
drug
therapy
available.
Studies
have
found
that
cannabidiol
(CBD)
can
improve
hyperactive
cognitive
symptoms
children
ASD.
However,
little
known
about
the
effect
of
CBD
combination
other
medications,
such
as
risperidone
(RISP).
This
study
aimed
to
evaluate
behavioral
biochemical
effects
animals
using
a
valproic
acid
(VPA)‐induced
ASD
animal
model.
VPA
was
administered
pregnant
Wistar
rats
on
Day
12.5
gestation
induce
From
10th
16th
postnatal
day
(PND),
neurodevelopment
assessed
through
eye‐opening,
olfactory
discrimination,
negative
geotaxis
tests.
PNDs
9
54,
were
weighed.
They
treated
for
21
days
alone
(100
mg/kg,
gavage,
twice
day)
or
RISP
(0.1
once
day).
At
PND
55,
evaluated
interaction
locomotor
activity
experiments.
Finally,
after
assessment,
euthanized,
brain
isolated,
oxidative
stress
parameters
hippocampus
cortex
posterior.
Animals
exposed
showed
neurodevelopmental
delays
opening
their
eyes,
difficulties
turning
around
axis,
took
longer
time
find
original
nest
when
compared
control
animals.
also
exhibited
impaired
sociability
reduced
exploratory
activity,
which
indicates
model
impairments.
Interestingly,
+
significantly
improved
parameters,
whereas
isolated
did
not
affect
this
parameter.
In
analysis,
significant
decrease
hippocampal
sulfhydryl
content
noted
CT
group
an
increase
group.
conclusion,
these
results
suggest
CBD,
RISP,
may
be
interesting
pharmacological
approach
reducing
ASD‐related
symptoms.
Summary
:
Besides
increased
prevalence
cases
recent
years,
there
are
medications
central
autism.
Numerous
studies
discuss
important
medication
improving
symptoms;
however,
it
how
interacts
commonly
used
drugs
individuals,
RISP.
demonstrated
therapy,
only
combined
VPA‐induced